Form 4: Lyell Immunopharma Grants General Counsel 50,000 Stock Options

Lyell Immunopharma's General Counsel, Mark A. Meltz, received a grant of options to purchase 50,000 shares of common stock with a specified vesting schedule.

Summary

• Mark A. Meltz, General Counsel of Lyell Immunopharma, Inc. (LYEL), was granted options to purchase 50,000 shares of common stock.
• The exercise price for these options is $23.71 per share.
• The transaction date for the option grant was February 10, 2026.
• The options have an expiration date of February 9, 2036.
• Vesting begins six months after February 9, 2026, with 12.5% of the shares vesting, followed by monthly vesting of 1/48th of the shares until fully vested, contingent on continued service.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as it represents routine executive compensation that aligns management incentives with shareholder value, without introducing new material information.

Positives

• The option grant aligns the General Counsel's financial interests with those of shareholders, incentivizing long-term performance.
• It represents a standard component of executive compensation, aiding in talent retention.

Negatives

• Potential future dilution for existing shareholders if the options are exercised, though this is a common aspect of equity compensation.

Future Outlook

The option grant, with its vesting schedule, indicates an expectation of continued service from the General Counsel and is designed to incentivize long-term commitment and performance aligned with company growth.

Industry Context

StockSavvy.ai notes that granting stock options to key executives like the General Counsel is a common practice in the biotechnology and pharmaceutical industries to attract, retain, and motivate talent, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• The grant of 50,000 stock options to a General Counsel is within the typical range for executive compensation packages in the biotech sector, comparable to grants seen at companies like Moderna or BioNTech for similar roles, though specific values vary based on company size and executive experience.
• The vesting schedule, with an initial cliff and subsequent monthly vesting over several years, is a standard mechanism used across the industry to ensure long-term retention and performance incentives.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned management incentives.
• Employees (specifically Mark A. Meltz): Receives significant equity compensation, enhancing personal wealth potential and incentivizing long-term commitment.

Next Steps

• The options will begin vesting six months after February 9, 2026, with 12.5% of the shares becoming exercisable.
• Following the initial vesting, an additional 1/48th of the shares will vest monthly, contingent on the General Counsel's continued service to the Issuer.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a company officer, which is a standard compensation practice. It does not contain new material information that would fundamentally alter the investment thesis or warrant a change in recommendation.

Keywords

Lyell Immunopharma, LYEL, Stock Options, Executive Compensation, Insider Transaction, Form 4, Mark A. Meltz, General Counsel, Equity Grant, Biotechnology